Aventa FusionPlus

Reveals actionable gene fusions & rearrangements missed by other methods

FFPE solid tumor tissue | Whole-genome | Reports on 361 genes

The Aventa FusionPlus test empowers you to detect gene fusions and rearrangements in solid tumors missed by FISH and standard DNA and RNA sequencing methods so that you can:

Determine therapy eligibility | Provide definitive diagnosis | Understand prognosis

2x

yield of therapeutic targets

The Aventa FusionPlus test increases the
diagnostic yield of fusions targeted by
FDA-approved therapies by 2x

>20% 

The Aventa FusionPlus test has been shown to detect an actionable gene fusion or rearrangement in >20% of patients who tested negative by other methods

Case study

Diagnosis: Cervix – Spindle cell sarcoma

  • DNA sequencing negative for driver mutations

  • Aventa FusionPlus found an NTRK3 fusion (intronic) and an ATM fusion

  • Both missed because breakpoint not targeted by DNA-seq probes

  • Patient recurred after surgery, received entrectinib based on Aventa FusionPlus results, continues treatment after two years

Aventa FusionPlus guided targeted therapy

Clinical diagnosis: Uterine smooth muscle tumor of uncertain malignant potential (STUMP)

  • Pathological diagnosis made based solely on IHC; patient received surgery followed by hormone therapy

  • Retrospective Aventa FusionPlus testing detected PRLR::PLAG1 fusion, favoring a diagnosis of leiomyosarcoma (LMS)

  • This change in diagnosis would have informed a different course of therapy – surgery followed by observation only

Aventa FusionPlus would have changed diagnosis and therapy selection

Original diagnosis: High-grade endometrial stromal sarcoma (HGESS)

  • Translocation-negative by DNA-seq and RNA-seq

  • Retrospective Aventa FusionPlus testing identified EPC1 fusion consistent with the diagnosis of low-grade endometrial stromal sarcoma (LGESS)

  • Change in prognosis from HGESS would have informed a change in patient management to hormone therapy and EBRT-only instead of systemic chemotherapy

Aventa FusionPlus would have changed prognosis and therapy selection

Clinical diagnosis: Myxoid sarcoma, favor myxoid LMS

  • Diagnosis was not definitive due to negative RNA sequencing

  • Retrospective Aventa FusionPlus testing identified PLAG1 rearrangement (undetectable by RNA sequencing due to lack of fusion transcript)

  • Results would have led to definitive diagnosis and confirmed need for systemic therapy in recurrent setting

Aventa FusionPlus would have provided definitive diagnosis

Standard techniques vs Aventa FusionPlus

Conventional techniques miss actionable variants

The technical limitations of standard techniques for fusion and rearrangement detection lead to a substantial number of actionable variants being missed:

  • Targeted DNA sequencing (e.g., CGP) — poor sensitivity for fusions and rearrangements

  • RNA sequencing — detects only expressed gene fusions, missing all other rearrangements; RNA is also not stable

  • Fluorescent in situ hybridization (FISH) — low resolution, need to anticipate targets, limited to a few targets

Aventa FusionPlus finds what other tests miss

The technology used in Aventa clinical tests is not susceptible to any of the limitations of standard techniques:

  • 100-1000 times higher signal compared to RNA or DNA sequencing or FISH, resulting in superior sensitivity

  • Variants detected regardless of where breakpoints occur or the identity of the individual fusion partners

  • Robust to sample quality issues seen with other assays

Ordering Aventa tests is easy

We handle specimen retrieval and return, and results are returned in about 10 business days.

We are committed to making our tests accessible and affordable

Aventa Assist offers programs to help patients whose costs for Aventa tests are not fully covered by insurance.